Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00221
|
|||||
| Drug Name |
Olaparib
|
|||||
| Synonyms |
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; AZD 2281; AZD-2281; AZD2281; Acylpiperazine analogue, 47; KU-0059436; KU-59436; Olaparib, KU-0059436, AZD2281,KU0059436, AZD2281
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Breast cancer [ICD11: 2C60-2C6Z] | Approved | [1] | |||
| Ovarian cancer [ICD11: 2C73] | Approved | [1] | ||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H23FN4O3
|
|||||
| Canonical SMILES |
C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F
|
|||||
| InChI |
InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)
|
|||||
| InChIKey |
FDLYAMZZIXQODN-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 763113-22-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 434.5 | Topological Polar Surface Area | 82.1 | ||
| Heavy Atom Count | 32 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
1.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103605183
, 109692964
, 117670453
, 118049496
, 121277945
, 123051082
, 124490470
, 124756970
, 124947876
, 125163775
, 125312522
, 125415525
, 126582065
, 126626885
, 126644879
, 126664211
, 126666996
, 126738835
, 131407195
, 131465127
, 134213960
, 134222742
, 134338825
, 134339140
, 134346179
, 134964396
, 135261055
, 135697767
, 135708109
, 135723596
, 135727477
, 136368068
, 136377786
, 136895641
, 136920280
, 137005640
, 137255348
, 141853509
, 143499369
, 144115666
, 152237700
, 152258100
, 152344243
, 160646939
, 47209066
, 56053773
, 57299275
, 85197660
, 93581006
, 99436961
|
|||||
| ChEBI ID |
CHEBI:83766
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Olaparib was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 May 7;12(7):871-878. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.